share_log

Eiger BioPharmaceuticals And 2 Other Penny Stocks Insiders Are Aggressively Buying

Eiger BioPharmaceuticals And 2 Other Penny Stocks Insiders Are Aggressively Buying

Eiger BioPharmaceuticals 和其他两只细价股内部人士正在积极买入
Benzinga Real-time News ·  2023/01/26 22:24

The Dow Jones closed slightly higher on Wednesday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.

道琼斯指数周三收盘小幅上涨。当内部人士购买或出售股票时，这表明他们对公司前景的信心或担忧。对细价股感兴趣的投资者和交易者可以将其视为影响其整体投资或交易决策的一个因素。

Below is a look at a few recent notable insider transactions for penny stocks. For more, check out Benzinga's insider transactions platform.

以下是近期一些值得注意的细价股内幕交易。欲了解更多，请查看 本辛加的内幕交易 平台。

Eiger BioPharmaceuticals

艾格生物制药

  • The Trade: Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR) Director Thomas J. Dietz bought a total of 50,000 shares at an average price of $1.43. To acquire these shares, it cost around $71.58 thousand.
  • What's Happening: Eiger BioPharmaceuticals said on January 3, 2023, Sriram Ryali notified the company of resignation as Chief Financial Officer effective Jan. 20, 2023.
  • What Eiger BioPharmaceuticals Does: Eiger BioPharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of drugs for serious, rare, and ultra-rare diseases with high unmet medical needs and no approved therapies.
  • 交易： 艾格生物制药有限公司 （纳斯达克股票代码：EIGR）导演 Thomas J. Dietz 共购买了5万股股票 平均价格为1.43美元。收购这些股票的成本约为71.58万美元。
  • 发生了什么： Eiger BioPharmaceuticals表示，Sriram Ryali于2023年1月3日通知该公司辞去首席财务官的职务，自2023年1月20日起生效。
  • 艾格生物制药是做什么的： Eiger BioPharmaceuticals Inc是一家处于商业阶段的生物制药公司，专注于为医疗需求未得到满足且未获批准的疗法的严重、罕见和超罕见疾病的药物的开发和商业化。

Adamas One

阿达玛斯一号

  • The Trade: Adamas One Corp. (NASDAQ:JEWL) President and CEO John Grdina acquired a total of 40,000 shares at an average price of $2.67. The insider spent around $106.78 thousand to buy those shares.
  • What's Happening: On the heels of its initial public offering, Adamas One reported $1.78 million in initial lab grown diamond sales for FY22.
  • What Adamas One Does: Adamas One Corp is a high-tech diamond company that uses its proprietary technology to produce high-quality, single-crystal diamonds and diamond materials through a CVD process, which it refers to as Diamond Technology.
  • 这笔交易: 阿达玛斯一号公司 （纳斯达克股票代码：JEWL）总裁兼首席执行官约翰·格尔迪纳 共收购了 40,000 股股份 平均价格为2.67美元。知情人士花了大约106.78万美元购买了这些股票。
  • 发生了什么：在首次公开募股之后，Adamas One报告称，22财年实验室培育的钻石初始销售额为178万美元。
  • Adamas One 做了什么: Adamas One Corp是一家高科技钻石公司，它利用其专有技术通过CVD工艺（它称之为钻石技术）生产高质量的单晶钻石和钻石材料。

Check This Out: 5 Most Expensive Energy Stocks You Should Worry About

看看这个： 你应该担心的 5 只最昂贵的能源股

Biomerica

Biomerica

  • The Trade: Biomerica, Inc. (NASDAQ:BMRA) CEO Zackary Irani acquired a total of 2,000 shares at an average price of $2.81. To acquire these shares, it cost around $5.62 thousand.
  • What's Happening: Biomerica, last month, received Kingdom of Saudi Arabia Food And Drug Administration and Ministry of Health approval for colorectal screening and breast screening tests in Saudi Arabia and UAE.
  • What Biomerica Does: Biomerica Inc is engaged in the development, manufacturing, and marketing of medical diagnostic products designed for the early detection and monitoring of chronic diseases and medical conditions.
  • 这笔交易: Biomerica, Inc. 纳斯达克股票代码：BMRA）首席执行官扎卡里·伊拉尼 共收购了 2,000 股股票 平均价格为2.81美元。收购这些股票的成本约为5.62万美元。
  • 发生了什么: 上个月，Biomerica获得了沙特阿拉伯王国食品药品监督管理局和卫生部的批准，可以在沙特阿拉伯和阿联酋进行结直肠筛查和乳房筛查测试。
  • Biomerica 做了什么: Biomerica Inc从事医疗诊断产品的开发、制造和销售，这些产品旨在早期发现和监测慢性病和疾病。

Don't forget to check out our premarket coverage here

别忘了在这里查看我们的上市前报道

译文内容由第三方软件翻译。


以上内容仅用作资讯或教育之目的，不构成与富途相关的任何投资建议。富途竭力但不能保证上述全部内容的真实性、准确性和原创性。
    抢沙发